by Entheon Biomedical | Oct 30, 2020 | Industry News
With all eyes on the US election, we are sure that those in the psychedelic medicine sphere wonder what this could mean for the future of psychedelic medicine in the United States. The US is home to many crucial networks and institutes that are moving the psychedelic...
by Entheon Biomedical | Oct 27, 2020 | Industry News
Worldwide, substance use disorders are on the rise, causing a high financial and social cost, yet the current model helps only a fraction of those suffering. Substance use disorders have exacerbated overcrowding of the healthcare system, which has forced policymakers...
by Entheon Biomedical | Sep 25, 2020 | Industry News
The toll of the opioid crisis begins in the home and community, destroying lives, picking away at the very fabric which holds us together as a people. From there, the collateral damage extends into the economy and our civic institutions, imposing a financial and...
by Entheon Biomedical | Aug 27, 2020 | Industry News
Written by Jessica Cadoch Opioids don’t discriminate—opioid misuse affects all Canadians On August 12, we wrote about the current opioid crisis and the uptick on opioid-related overdoses and deaths in Canada. This crisis does not discriminate against minority...
by Entheon Biomedical | Aug 12, 2020 | Industry News
Written by Jessica Cadoch Oxycodone, Codeine, Morphine and Heroin are all classified opiates. These substances are procedurally offered by medical experts as painkillers and seek to relieve patients from deep suffering. However, these substances are also highly...
by Entheon Biomedical | Jun 18, 2020 | Industry News
The world is experiencing a devastating physical health emergency. But the coronavirus pandemic has also seen a renewed focus on our psychological wellbeing. Loneliness, uncertainty and grief may be intensifying an already acute mental health crisis, and in the US...
Recent Comments